GAMMAGARD LIQUID is indicated as a therapy to improve neuromuscular disability and impairment in adult patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

LIMITATIONS OF USE:  GAMMAGARD LIQUID has not been studied in immunoglobulin-naive patients with CIDP. GAMMAGARD LIQUID maintenance therapy in CIDP has not been studied for periods longer than 6 months. After responding during an initial treatment period, not all patients require indefinite maintenance therapy with GAMMAGARD LIQUID in order to remain free of CIDP symptoms. Individualize the duration of any treatment beyond 6 months based upon the patient’s response and demonstrated need for continued therapy.

Intended for US Healthcare Professionals only

    Identifying CIDP

    CIDP = chronic inflammatory demyelinating polyneuropathy.

    About CIDP

    CIDP is a rare, immune-mediated, progressive motor neuropathy that can cause the immune system to attack the nerves, causing muscle weakness and numbness.1 A CIDP diagnosis can be elusive, because CIDP symptoms can be similar to those of other neurological disorders.2 In fact, ~68% of patients with CIDP received an alternative diagnosis in a study, with a mean diagnostic delay of 21.3 months.2

    But, paying attention to those symptoms can help reveal CIDP’s presence. If your patient experiences these symptoms for longer than 8 weeks, you may want to consider testing for CIDP.3

    People living with CIDP may experience the following symptoms3:

    These symptoms may be recurrent and worsen over time.

    Arm and leg weakness icon.

    Arm/leg weakness

    Balance icon.

    Difficulty with balance

    Fine motor skills icon.

    Difficulty with
    fine motor skills

    Coordination icon.

    Loss of coordination

    Walking aid usage icon.

    Walking aid usage

    Patients with CIDP may struggle with daily tasks such as3:

    Handling small coins icon.

    Handling small coins

    Hairbrush icon.

    Brushing hair

    Key icon.

    Turning a key in a lock

    Zipper icon.

    Working a zipper or buttons

    Washing hair icon.

    Washing hair

    Shoe icon.

    Tying their shoes

    Utensil icon.

    Holding a cup and gripping
    utensils

    Cell phone icon.

    Texting and typing

    Sign icon.

    Choosing an appropriate therapy

    Takeda has a portfolio of IG therapies designed with different CIDP patient needs in mind.

    Learn more

    References:

    1. GAMMAGARD LIQUID. Prescribing Information. Takeda Pharmaceuticals U.S.A, Inc.; 2024.
    2. Umair J Chaudhary, Yusuf A. Rajabally. Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy. November 10, 2020.
    3. Chronic Inflammatory Demyelinating Polyneuropathy: John Hopkins Medicine. https://www.hopkinsmedicine.org/health/conditions-and-diseases/chronic-inflammatory-demyelinating-polyradiculoneuropathy/. Accessed February 27, 2025.